Elsevier

The Lancet HIV

Volume 4, Issue 9, September 2017, Pages e402-e410
The Lancet HIV

Articles
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

https://doi.org/10.1016/S2352-3018(17)30089-9Get rights and content

Summary

Background

Data for on-demand pre-exposure prophylaxis (PrEP) are scarce. We implemented a cohort study to assess its efficacy, safety, and effect on sexual behaviour.

Methods

We invited men and transgender women who have sex with men, previously enrolled in the randomised placebo-controlled ANRS IPERGAY trial at seven sites (six in France and one in Canada), to participate in an open-label extension with on-demand tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) to be taken before and after sexual intercourse. We assessed the incidence of HIV and other sexually transmitted infections (STIs), PrEP adherence, safety, and sexual behaviour. Statistical analyses included comparisons of proportions and incidence between the randomised phase of the ANRS IPERGAY trial and the open-label phase, and all participants were included in safety analyses. ANRS IPERGAY is registered with ClinicalTrials.gov, number NCT01473472.

Findings

Between Nov 4, 2014, and Jan 27, 2015, we enrolled 361 participants. Median follow-up was 18·4 months (IQR 17·7–19·1). One participant who discontinued PrEP acquired HIV infection. HIV incidence was 0·19 per 100 person-years (95% CI 0·01–1·08), compared with 6·60 per 100 person-years (3·60–11·05) in the placebo group of the randomised study, indicating a relative reduction of 97% (95% CI 81–100) in the incidence of HIV with on-demand PrEP. Participants used a median of 18 pills of study drugs per month (IQR 11–25), and at the 6 month visit 240 (71%) of 336 participants had tenofovir detected in plasma. Drug-related gastrointestinal events were reported in 49 participants (14%) but were self-limited. Only four participants (1%) discontinued PrEP, three because of an increase in plasma creatinine. The proportion of participants reporting condomless sex at their last receptive anal intercourse significantly increased from 77% (136 of 176 participants) at baseline to 86% (66 of 77 participants) at 18 months' follow-up (p for trend=0·0004). The incidence of a first bacterial STI during this open-label phase did not change significantly compared with the randomised phase (59·0 vs 49·1 per 100 person-years, respectively; p=0·11).

Interpretation

On-demand oral PrEP is highly effective at preventing HIV infection among high-risk men who have sex with men and therefore represents an alternative to daily PrEP, expanding choices for HIV prevention. High rates of STIs resulting from low condom use did not undermine PrEP efficacy, but warrant frequent testing.

Funding

ANRS (France Recherche Nord and Sud Sida-HIV Hépatites), the Canadian HIV Trials Network, Fonds Pierre Bergé—Sidaction, Gilead Sciences, and the Bill & Melinda Gates Foundation.

Introduction

With an estimated 1·9 million new HIV infections worldwide in 2015, HIV prevention urgently needs to be strengthened.1 Daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine provides efficient protection against HIV infection among men who have sex with men (MSM), heterosexual men and women, intravenous drug users, and HIV-negative partners among serodiscordant couples.2, 3, 4, 5, 6 PrEP is recommended by WHO as an additional prevention choice for people at substantial risk of HIV infection and is approved for use in several countries.7 However, like other preventive approaches, PrEP efficacy is strongly associated with adherence, and some individuals might not be able to take daily pills for long periods of time, thereby compromising PrEP efficacy.8, 9

To overcome this issue of adherence, alternatives to daily oral PrEP are being developed and these include vaginal or rectal gels, vaginal rings, injectable antiretrovirals, and even implants.10, 11, 12 However, the approval and availability of these methods will take many years. In the meantime, intermittent PrEP, taken at the time of sexual activity, might expand choices for people willing to use oral PrEP without being committed to a daily regimen.

A single efficacy trial, the ANRS IPERGAY trial,13 was done among high-risk MSM in France and Canada to assess on-demand PrEP with tenofovir disoproxil fumarate and emtricitabine. The results of the intention-to-treat analysis showed an 86% relative reduction of HIV incidence compared with placebo. However, because of this high efficacy, treatment for the placebo group in this trial was prematurely discontinued after a median follow-up of only 9·3 months; therefore, one cannot dismiss the possibility of an overestimation of PrEP efficacy in this study because of high initial adherence, and more data are needed to confirm the efficacy of PrEP on demand. Additionally, more follow-up data are required to assess the long-term safety of this intervention among MSM, its effect on sexual behaviour and condom use, and the consequences in terms of the incidence of other sexually transmitted infections (STIs), an increasing concern among MSM who use PrEP.14 Now that efficacy is well established, PrEP use and sexual practices could differ in open-label cohort studies compared with trials.

Research in context

Evidence before this study

Daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine is recommended by WHO and the US Centers for Disease Control and Prevention as an additional prevention tool for people at substantial risk of HIV infection, including men who have sex with men (MSM), heterosexual men and women, intravenous drug users, and HIV-negative partners in serodiscordant couples. PrEP efficacy is strongly associated with adherence, but some individuals might not be able to take daily pills for long periods of time. On-demand PrEP, taken at the time of sexual activity, might represent an interesting option for people willing to use oral PrEP without being committed to a daily regimen. A single efficacy trial, the ANRS IPERGAY trial, done among high-risk MSM in France and Canada showed an 86% (95% CI 40–98) relative reduction of HIV incidence with on-demand tenofovir disoproxil fumarate and emtricitabine compared with placebo. However, because this single trial was prematurely discontinued after a median follow-up of only 9·3 months, one cannot dismiss the possibility of an overestimation of PrEP efficacy due to high initial adherence to PrEP, and more data are needed to confirm the efficacy of PrEP on demand.

We searched PubMed with no language restrictions until Jan 27, 2017, with the terms “on demand pre exposure prophylaxis and HIV” or “intermittent”, “event driven”, “sex driven”, “time driven”, “pre exposure prophylaxis”, and “HIV”. This search yielded 91 publications. We also reviewed all trials of non-daily (event or time-driven) oral PrEP listed in the AVAC HIV Prevention Research and Development Database, which has comprehensive information on clinical trials of HIV prevention either planned, ongoing, or completed. We identified several completed and ongoing studies and demonstration projects designed to assess acceptability, safety, people preferences, pharmacokinetic models, and adherence to intermittent PrEP, but none were designed to assess efficacy. Numerous cost-effectiveness studies with intermittent PrEP have also been done.

Added value of this study

This open-label extension of the ANRS IPERGAY trial immediately followed the end of the double-blind phase of the study and all participants were offered to receive open-label on-demand PrEP. With approximately twice the number of individuals using on-demand PrEP (n=361) for a median duration of follow-up, which was also twice that of the double-blind phase (18·4 months), these results confirm and extend the effectiveness of on-demand PrEP previously reported. Indeed, the incidence of HIV infection among MSM in our study was low (0·19 case per 100 person-years), representing a 97% (95% CI 81–100) relative reduction of HIV incidence compared with the incidence in the placebo group of the double-blind phase. Additionally, the safety of on-demand treatment was good, with only 1% of participants discontinuing PrEP mainly because of a reduced plasma creatinine clearance. Furthermore, despite a reduced use of condoms, the incidence of sexually transmitted infections did not increase during this open-label extension study.

Implications of all the available evidence

On-demand tenofovir disoproxil fumarate and emtricitabine is an effective and safe alternative to daily oral PrEP with tenofovir disoproxil fumarate and emtricitabine among MSM and will expand their choices for PrEP. Research is ongoing to assess this on-demand regimen in other high-risk groups (heterosexual men and women). On-demand PrEP is recommended only in Europe and Canada among MSM, but results of this study might also inform guidelines.

Immediately after discontinuation of the placebo-controlled randomised phase of the ANRS IPERGAY trial on demonstration of efficacy of intermitted dosing, we offered study participants enrolment in a cohort to better understand real-world use and to enable them to retain access of PrEP until regulatory approval and public reimbursement in France and Quebec.

Section snippets

Study design and participants

We enrolled participants to this cohort study from the ANRS IPERGAY trial13 who remained under follow-up at the time of discontinuation of the randomised placebo-controlled phase of the study in November, 2014. All participants in the screening period who had not yet been randomly assigned were also eligible, as long as they met all the inclusion criteria for the double-blind trial. Briefly, we enrolled HIV-negative MSM or transgender women having sex with men, aged 18 years or older, who were

Results

Between Nov 4, 2014, and Jan 27, 2015, we enrolled 361 participants from the 400 participants who started the randomised placebo-controlled phase of the study13 and new participants who had been screened for enrolment in the double-blind phase. The last follow-up visit was on June 30, 2016 (figure 1). All participants were male except for two transgender women (table 1).

During the study period, 63 participants (17%) prematurely discontinued the study. 518 person-years of follow-up was accrued

Discussion

The results of this open-label study extension done in high-risk MSM and transgender women who have sex with men using on-demand oral PrEP with tenofovir disoproxil fumarate and emtricitabine confirm and extend the results of the previous placebo-controlled randomised study.13 HIV incidence in this cohort was low and was lower than the HIV incidence reported in the active and placebo groups of the randomised phase.13 This low incidence is a 97% reduction in risk of HIV acquisition relative to

References (24)

  • L Van Damme et al.

    Preexposure prophylaxis for HIV infection among African women

    N Engl J Med

    (2012)
  • Q Abdool Karim et al.

    Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

    Science

    (2010)
  • Cited by (360)

    View all citing articles on Scopus

    Prof Wainberg died in April, 2017

    *

    Members are listed at the end of the paper

    View full text